HRMY (Harmony Biosciences Holdings) LT-Debt-to-Total-Asset : 0.16 (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Harmony Biosciences Holdings LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Harmony Biosciences Holdings's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.16.

Harmony Biosciences Holdings's long-term debt to total assets ratio declined from Dec. 2023 (0.22) to Dec. 2024 (0.16). It may suggest that Harmony Biosciences Holdings is progressively becoming less dependent on debt to grow their business.

Harmony Biosciences Holdings LT-Debt-to-Total-Asset Historical Data

The historical data trend for Harmony Biosciences Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harmony Biosciences Holdings LT-Debt-to-Total-Asset Chart

Harmony Biosciences Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.46

0.44

0.28

0.22

0.16

Harmony Biosciences Holdings Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.22	0.21	0.20	0.18	0.16

Harmony Biosciences Holdings LT-Debt-to-Total-Asset Calculation

Harmony Biosciences Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	163.016	/	999.2
	=	0.16

Harmony Biosciences Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	163.016	/	999.2
	=	0.16

Harmony Biosciences Holdings (NAS:HRMY) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Harmony Biosciences Holdings LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Harmony Biosciences Holdings's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Harmony Biosciences Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Harmony Biosciences Holdings Inc (NAS:HRMY) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA, USA, 19462

Website

https://www.harmonybiosciences.com

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Executives

Jeffrey Dierks	officer: Chief Commercial Officer	630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Sandip Kapadia	officer: Chief Financial Officer	450 WEST 15 STREET, SUITE 505, NEW YORK NY 10011
Jeffrey M. Dayno	officer: Chief Medical Officer	460 EAST SWEDESFORD ROAD, SUITE 1050, WAYNE PA 19087
Marshman Fund Trust Ii	10 percent owner	630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Valor Iv Pharma Holdings, Llc	10 percent owner	875 N. MICHIGAN AVENUE, SUITE 3214, CHICAGO IL 60611
Peter Anastasiou	director	C/O HARMONY BIOSCIENCES HOLDINGS, INC., 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Andreas Wicki	director	C/O HBM BIOVENTURES (CAYMAN) LTD., CENTENNIAL TOWERS,STE.305,2454 W.BAY RD., GRAND CAYMAN E9 E9
Jack Nielsen	director	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Andrew Serafin	officer: Chief Business Officer	630 W. GERMANTOWN PIKE, PLYMOUTH MEETING PA 19462
John C Jacobs	director, officer: President, CEO	630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Linda M Szyper	director	C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 250, SUITE 400, GRAND PRAIRIE TX 75050
Eric L Motley	director	1516 33RD STREET NW, WASHINGTON DC 20007
R. Mark Graf	director	C/O DISCOVER FINANCIAL SERVICES, 2500 LAKE COOK ROAD, RIVERWOODS IL 60015
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Valor Management L.p.	10 percent owner	875 N. MICHIGAN AVENUE, SUITE 3214, CHICAGO IL 60611